

2 0 1 2
 5th PARIS
HEPATITIS
CONFERENCE

Organised by Pr Patrick Marcellin

Organising Committee:
Tarik Asselah, Nathalie Boyer, Michelle Martinot

**Hôpital Beaujon, AHPH
Université Paris - Diderot
INSERM CRB3**

30 & 31 January 2012

PARIS - Palais des Congrès



www.aphc.info



Dear colleagues,

The fifth Paris Hepatitis Conference (PHC) to be held on January 30 & 31, 2012, is a special edition dedicated to the management of patients with hepatitis C. Outstanding international experts will be reviewing the most up-to-date information and provide their personal recommendations for the clinical care of these patients.

Recently, the management of chronic hepatitis C has benefitted from spectacular advances provided by the results of phase 3 studies of triple therapy with protease inhibitors, telaprevir or boceprevir, in naïve and experienced patients with hepatitis C virus (HCV) genotype 1. Thus, triple therapy has now become the new standard of care in this population of patients.

Current triple therapy is targeted to HCV genotype 1. However, in many countries, there are large, sometimes very predominant, populations infected with HCV non-1 genotypes. Several sessions and discussions will focus on the optimal management of patients infected with genotypes 2, 3, or 4.

The therapy of hepatitis C is evolving rapidly. New antivirals and new combinations thereof are about to appear, either for genotype 1, or for other genotypes. The most recent studies will be presented and discussed to give the hepatologist the decision-making tools for the future. In addition, the meeting will devote specific sessions and workshops for those difficult-to-treat patient populations that require an individualized treatment approach.

The aim of this 5th PHC is to provide clinicians with state-of-the-art information as well as highly practical and relevant clinical guidance to optimize the management of hepatitis C for the ultimate benefit and cure of as many patients as possible, worldwide.

I wish you a most pleasant stay in Paris and a very fruitful meeting,

Best wishes,

Patrick Marcellin
President of the 5th Paris Hepatitis Conference

WHERE WE ARE

8:30 Introduction: Hepatitis C: A big step towards eradication

Patrick Marcellin (France)

8:45 - 10:20 Triple therapy today. Phase III results in G1 naive patients

Chairpersons: Massimo Colombo (Italy) and Michael Manns (Germany)

- 8:45 ■ Telaprevir *Ira Jacobson (USA)*
- 9:05 ■ Boceprevir *Michael Manns (Germany)*
- 9:25 ■ Safety management in clinical practice *Christophe Hezode (France)*
- 9:40 ■ Clinical relevance of predictors *Paul Kwo (USA)*
- 9:55 ■ Round table

 10:20 - 10:50 Coffee break

10:50 - 12:00 Triple therapy today. Phase III results in G1 relapsers and non responders

Chairpersons: Geoffrey Dusheiko (UK) and Eugene Schiff (USA)

- 10:50 ■ Telaprevir *Stefan Zeuzem (Germany)*
- 11:10 ■ Boceprevir *Bruce Bacon (USA)*
- 11:30 ■ Round table

12:00 - 12:30 State of the art lecture

Chairman: Patrick Marcellin (France)

- The EASL HCV Clinical Practice Guidelines *Antonio Craxi (Italy)*

12:30 - 14:30

Interactive Luncheons

14:30 - 15:30 What's new in Non G1?

Chairpersons: Jia Horng Kao (Taiwan) and Alfredo Alberti (Italy)

- 14:30 ■ Genotype 2 *Alessandra Mangia (Italy)*
- 14:45 ■ Genotype 3 *Shiv Kumar Sarin (India)*
- 15:00 ■ Genotype 4 *Gamal Esmat (Egypt)*
- 15:15 ■ Round table

 15:30 - 16:00 Coffee break

16:00 - 17:00 Special populations

Chairpersons: Teerha Piratvisuth (Thailand) and Sam Lee (Canada)

- 16:00 ■ Cirrhotics *Marc Bourlière (France)*
- 16:15 ■ Pre and post liver transplantation *Didier Samuel (France)*
- 16:30 ■ HCV-HIV coinfection *Mark Sulkowski (USA)*
- 16:45 ■ Round table

17:00 State of the art lecture

- Introduction *Patrick Marcellin (France)*
- The history of HCV therapy *Jay Hoofnagle (USA)*

18:00 **Ajournement**

19:30 **Congress Dinner**

PROGRAMME OF THE WORKING LUNCHEONS

For people not registered to the working luncheons, regular lunches are also organised in Salons Concorde (Level 4)

January 30th, 2012 from 12:30 to 14:30

Room 241 - Level 2

1. Comment optimiser le traitement des patients naïfs ?

(French speaking luncheon)

Chairman: Patrice Couzigou (France)

Speakers: Najet Bel Hadj Brik (Tunisie),

Denis Ouzan (France),

Rachid Ould Gougam (Algérie)

Room 242A - Level 2

2. How to optimize treatment of G1 patients?

Chairman: Michael Fried (USA)

Speakers: Cihan Yurdaydin (Turkey),

George Lau (Hong Kong)

Room 242B - Level 2

3. How to optimize treatment of G2 and G3 patients?

Chairman: Shiv Kumar Sarin (India)

Speakers: Graham Foster (UK),

Alessio Aghemo (Italy)

Room 251 - Level 2

4. How to optimize treatment of G4 patients?

Chairman: Nezam Afdhal (USA)

Speakers: Philippe Mathurin (France),

Nabil Antaki (Syria),

Imam Waked (Egypt)

Room 252B - Level 2

5. How to manage G1 relapsers and non responders?

Chairman: Michael Manns (Germany)

Speakers: Jean-Pierre Bronowicki (France),

George Papatheodoridis (Greece)

Room 252A - Level 2

6. How to manage side effects of triple therapy?

Chairman: Donald Jensen (USA)

Speakers: Sam Lee (Canada),

Vincent Leroy (France)

Room 243 - Level 2

7. Future therapies

Chairman: Tarik Asselah (France)

Speakers: Massimo Levrero (Italy),

Francesco Negro (Switzerland),

Mark Sulkowski (USA)

Room 253 - Level 2

8. Non invasive markers of fibrosis

Chairman: Pierre Bedossa (France)

Speakers: Victor de Ledinghen (France),

Ana Carolina Cardoso (Brazil),

Paul Cales (France)

January 31st, 2012 from 12:30 to 14:30

Room 241 - Level 2

1. Comment optimiser la prise en charge des patients rechuteurs et non répondeurs ?
(French speaking luncheon)

Chairman: Christian Trepo (France)

Speakers: Mustapha Bennazouz (Maroc),

Mihai Voiculescu (Roumanie),

Albert Tran (France)

Room 252A - Level 2

2. How to optimize treatment of G1 patient?

Chairman: Antonio Craxi (Italy)

Speakers: Marina Berenguer (Spain),

Sherif Abd El-Fattah (Egypt),

Andrzej Horban (Poland)

Room 242B - Level 2

3. How to optimize treatment of non G1 patient?

Chairman: Massimo Colombo (Italy)

Speakers: Alessandra Mangia (Italy),

Rami Moucari (Lebanon)

Room 243 - Level 2

4. How to avoid a resistance issue?

Chairman: Mitchell Shiffman (USA)

Speakers: Olivier Lada (France),

Fabien Zoulim (France)

Room 252B - Level 2

5. How to manage non responders and relapsers?

Chairman: Alfredo Alberti (Italy)

Speakers: Maria Buti (Spain),

Lawrence Serfaty (France)

Room 242A - Level 2

6. How to manage side effects of triple therapy?

Chairman: Eugene Schiff (USA)

Speakers: Ola Weiland (Sweden),

Vlad Ratziu (France)

Room 251 - Level 2

7. Future therapies

Chairman: David Nelson (USA)

Speakers: Ralf Bartenschlager (Germany),

Robert Flisiak (Poland)

Room 253 - Level 2

8. Treatment of patients with cirrhosis

Chairman: Dominique Valla (France)

Speakers: Laurent Castera (France),

Geoffrey Dusheiko (UK)

WHERE WE GO

8:30 Introduction

Patrick Marcellin (France)

8:45 - 10:15 **Controversies Part 1**

Chairpersons: Jean-Pierre Zarski (France) and Nezam Afdhal (USA)

8:45 ■ Telaprevir or Boceprevir?

Mitchell Shiffman (USA) – Rafael Esteban (Spain)

9:15 ■ Lead in or no lead in?

Lawrence Serfaty (France) – Graham Foster (UK)

9:45 ■ Response unguided or guided?

Raj Reddy (USA) – Fabien Zoulim (France)

 10:15 - 10:45 Coffee break

10:45 - 11:45 **Controversies Part 2**

Chairpersons: Mark Thursz (UK) and Masao Omata (Japan)

10:45 ■ Do IL28B or not do IL28B?

Stanislas Pol (France) – Donald Jensen (USA)

11:15 ■ Resistance is important: Yes or No?

Christoph Sarrazin (Germany) – Philippe Halfon (France)

11:45 **State of the art lecture**

■ Introduction: Is the game over?

Raymond Schinazi (USA)

■ New targets for antivirals against HCV

Ralf Bartenschlager (Germany)

12:30 - 14:30

Interactive Luncheons

14:30 - 15:00 **State of the art lecture**

Chairman: Tarik Asselah (France)

■ How to improve access to therapy?

Michael Fried (USA)

15:00 - 16:15 **The future**

Chairpersons: Ji Dong Jia (China) and Jake Liang (USA)

15:00 ■ Advantages of new generation DAAs

Tarik Asselah (France)

15:20 ■ Is Ribavirin still useful?

David Nelson (USA)

15:40 ■ Are interferons really necessary?

Peter Ferenci (Austria)

16:00 ■ Round table

16:15 - 16:30 Conclusion and perspectives

Patrick Marcellin (France)

GENERAL INFORMATION

CONFERENCES DATES AND VENUE

From Monday, 30 January 2012
To Tuesday, 31 January 2012
At the Palais des Congrès
1 place Maillot - 75017 Paris

CONFERENCE REGISTRATION DESK

30 & 31 January, from 7:00 am:
Welcome desks are organised on Level 2 of the Palais des Congrès, next to the Amphithéâtre Bleu. You will be able to register on site, retrieve your access badge, congress bag and proceedings.

29 January, from 10:00 am to 9:00 pm: Special Welcome desks are organised in the Lobby of the Meridien Etoile and of the Concorde Lafayette for all attendees staying at this hotel. You will be able to retrieve your access badge and your congress bag.

CONGRESS OFFICE

Colloquium/ PHC 2012
Congress Administrative Secretariat
13-15 rue de Nancy
75010 Paris - France
Tel.: + 33 (0)1 44 64 15 15
Fax: + 33 (0)1 44 64 15 16
phc2012@clq-group.com
www.aphc.info

CONGRESS HOTELS

Concorde Lafayette Hotel
3 place du Général Koenig
75017 Paris
Tel : + 33 (0)1 40 68 50 68

Méridien Etoile Hotel
81 boulevard Gouvion St-Cyr
75 017 Paris
Tel: +33 (0)1 40 68 34 34

CONGRESS DINNER

Monday, 30 January at the Cercle National des armées.
7:00 pm: buses departure from the official hotels.
Dress code: cocktail attire

CONTINUING MEDICAL EDUCATION (CME)

The "APHC" is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
The 5th Paris Hepatitis Conference is designated for a maximum of (or "for up to") 12 European CME credits (ECMEC).

LIVER INTERNATIONAL

The PHC Liver international supplement is available online at the following address:
<http://blackwellpublishing.com>

LUNCHEONS

2 types of lunches are organised each day:
- *Working Luncheons (Level 2).*
The number of seats is limited, an invitation card will be requested on entrance. Ask the welcome desk for registration, according to the luncheons sessions programme.
- *Regular luncheons* are organised in Salons Concorde (Level 4).

METRO and RER

The metro station (line 1) and RER station (line C) are located on level -1 of the Palais des Congrès: Porte Maillot station. The Conference will be held in Amphitheatre Bleu on level 2.

OFFICIAL LANGUAGE

The official language of the conference is English.

